본문으로 건너뛰기
cccskills
무료GitHub에 공개

es-cushing-screening-tests-for-hypercortisolism-recurrence

This skill recommends using biochemical tests to screen for hypercortisolism to detect recurrence in patients with ACTH-dependent Cushing's syndrome after surgical remission. It is triggered during postoperative follow-up when the HPA axis has recovered, annually, or sooner if clinical signs of hypercortisolism (e.g., weight gain, hypertension, glucose intolerance) or abnormal late-night salivary cortisol/UFC appear.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

설치 방법 보기

포함된 파일(1)

  • SKILL.md3.1 KB

SKILL.md(원문)

설치하기 전에 에이전트에게 전달되는 지시 내용을 확인할 수 있습니다.

Using Tests to Screen for Hypercortisolism to Assess for Recurrence in ACTH-Dependent Cushing's Syndrome

STEP 1 — Gather Information

Collect postoperative timing, HPA axis recovery status, symptoms (weight gain, hypertension, glucose intolerance, fatigue, mood changes), prior biochemical remission values, and imaging if available. Obtain late-night salivary cortisol, urine free cortisol (UFC), or low-dose dexamethasone suppression test per local protocol.

STEP 2 — Rule In / Rule Out

Is there a clinical suspicion of recurrence (new/significant symptoms) OR an abnormal screening test (late-night salivary cortisol > upper limit of normal, UFC > 2× ULN, or failure to suppress cortisol with dexamethasone)?

  • Yes: Proceed to confirmatory testing.
  • No: Continue routine surveillance (clinical assessment annually and biochemical testing every 6–12 months).

STEP 3 — Classify or Stratify

If screening test is abnormal, repeat the same test under standardized conditions (avoid stress, illness, medication interference).

  • Repeat normal: Consider false positive; maintain routine surveillance.
  • Repeat abnormal: Proceed to definitive evaluation (pituitary MRI, petrosal sinus sampling if ACTH-dependent source uncertain, or adrenal imaging if adrenal source suspected).

STEP 4 — Decide

If imaging confirms a lesion suggestive of recurrent ACTH source: discuss repeat transsphenoidal surgery, radiation therapy, medical therapy, or bilateral adrenalectomy based on lesion resectability, patient preference, and comorbidities.
If no lesion identified but biochemical evidence persists: consider empirical medical therapy (steroidogenesis inhibitor) or repeat imaging in 3–6 months.

Clinical Guardrails / Mimics / Pitfalls

Do not diagnose recurrence on a single abnormal test without confirmation due to assay variability, stress, or medication effects. Avoid overtreatment of borderline results; ensure HPA axis has recovered before interpreting cortisol levels. Do not neglect subtle symptoms (e.g., mild weight gain) as they may precede biochemical relapse.

Concrete Clinical Example

A 42‑year‑old woman with ACTH‑dependent Cushing’s disease underwent transsphenoidal surgery; 14 months postoperatively she reported 5 kg weight gain and new‑onset hypertension. Late‑night salivary cortisol was 1.8× ULN; repeat test remained elevated. Pituitary MRI showed a 6 mm enhancing lesion. She opted for repeat transsphenoidal surgery, achieving postoperative UFC < ULN and symptom resolution.

Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., 2015, DOI: 10.1210/jc.2015-1818

리뷰

아직 리뷰가 없습니다. 사용해 본 소감을 남겨 주세요.

댓글

로그인 없이 쓸 수 있습니다. 사용 후기, 질문, 작동하지 않은 환경 등을 편하게 남겨 주세요.

아직 댓글이 없습니다. 첫 댓글을 남겨 보세요.

보내면 바로 공개됩니다. 이메일 주소나 전화번호 같은 개인 정보는 쓰지 마세요. URL은 2개까지입니다.

0 / 1,000자

이 양식은 reCAPTCHA로 보호되며 Google 개인정보처리방침 및 서비스 약관이 적용됩니다.

같은 저장소의 스킬

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

dromlakhani의 스킬 모두 보기

이 스킬의 문제 신고